Disclosures for "Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study"
-
Dr. Podhorna has received personal compensation for serving as an employee of argenx. Dr. Podhorna has stock in argenx.
-
Dr. Ward has nothing to disclose.
-
Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Lee has received personal compensation in the range of $0-$499 for serving as a Consultant for Amylyx. Dr. Lee has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. The institution of Dr. Lee has received research support from Myasthenia Gravis Foundation of America. The institution of Dr. Lee has received research support from CReATe consortium/American Brain Foundation. The institution of Dr. Lee has received research support from NIH.
-
Dr. Li has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Li has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst. Dr. Li has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Li has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Li has received research support from Argenx.
-
Dr. Ruck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme.
-
Dr. Teperov has received personal compensation for serving as an employee of argenx.
-
Dr. Shah has nothing to disclose.
-
Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.